MarketResearchNest.com adds “Mild Cognitive Impairment – Pipeline Review, H2 2017” new report to its research database. The report spread across in 113 pages with table and figures in it.
Latest Pharmaceutical and Healthcare disease pipeline guide Mild Cognitive Impairment – Pipeline Review, H2 2017, provides an overview of the Mild Cognitive Impairment (Central Nervous System) pipeline landscape.
Mild cognitive impairment (MCI) is a condition involving problems with cognitive function (such as thinking, knowing and remembering). MCI is an intermediate stage between the expected cognitive decline of normal aging and the more serious decline of dementia. Symptoms include depression, irritability and aggression, anxiety and apathy. Risk factors include diabetes, high blood pressure, and depression, smoking and elevated cholesterol.
Enquiry for buying at: https://www.marketresearchnest.com/enquirybuy.php?reportid=260078
The Mild Cognitive Impairment (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Mild Cognitive Impairment and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 8, 6, 1, 14 and 1 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 2 and 1 molecules, respectively.
Mild Cognitive Impairment (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Companies mentioned in this report includes:
AgeneBio Inc, Avraham Pharmaceuticals Ltd, CereSpir Inc, ConSynance Therapeutics Inc, Eisai Co Ltd, Eli Lilly and Company, Ensol Biosciences Inc, Genzyme Corp, IntelGenx Corp, Krenitsky Pharmaceuticals Inc, Merck & Co Inc, Nanotherapeutics Inc, Neuron Biopharma SA, Pfizer Inc, Sage Therapeutics Inc, SBI Pharmaceuticals Co Ltd, Suven Life Sciences Ltd, Takeda Pharmaceutical Company Ltd, Therapix Biosciences Ltd
Order a Premium Purchase Report Copy at : https://www.marketresearchnest.com/purchase.php?reportid=260078
– The pipeline guide provides a snapshot of the global therapeutic landscape of Mild Cognitive Impairment (Central Nervous System).
– The pipeline guide reviews pipeline therapeutics for Mild Cognitive Impairment (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, RandD brief, MoA and other developmental activities.
– The pipeline guide reviews key companies involved in Mild Cognitive Impairment (Central Nervous System) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Mild Cognitive Impairment (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Mild Cognitive Impairment (Central Nervous System)
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective RandD strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Mild Cognitive Impairment (Central Nervous System).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Mild Cognitive Impairment (Central Nervous System) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Enquiry for Discount at: https://www.marketresearchnest.com/requestdiscount.php?reportid=260078
MarketResearchNest.com is the most comprehensive collection of market research products and services on the Web. We offer reports from almost all top publishers and update our collection on daily basis to provide you with instant online access to the world’s most complete and recent database of expert insights on global industries, organizations, products, and trends.
Mr. Jeet Jain
MarketResearchNest.com adds “Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) – Pipeline Review, H2 2017” new report to its research database. provides an overview of the Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) pipeline landscape.
MarketResearchNest.com adds “Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) – Pipeline Review, H2 2017” new report to its research database. provides an overview of the Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) pipeline landscape.